Evidence map›Paper›PMID 37764248›Full record

ArticleMolecules (Basel, Switzerland)2023

Evaluation of 4-Aminoquinoline Hydrazone Analogues as Potential Leads for Drug-Resistant Malaria.

Rachael N Magwaza, Muna Abubaker, Buthaina Hussain, Michael Haley, Kevin Couper, Sally Freeman, Niroshini J Nirmalan

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Molecules (Basel, Switzerland), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
2.3field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 8 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 2 countries.

Rachael N MagwazaDivision of Pharmacy and Optometry, School of Health Sciences, University of Manchester, Manchester M13 9PT, UK.ORCID 0000-0002-3634-6981
Muna AbubakerSchool of Science, Engineering and Environment, University of Salford, Manchester M5 4WT, UK.ORCID 0000-0003-2860-3797
Buthaina HussainFaculty of Pharmacy, Al-Zaytoonah University of Jordan, Amman 17138, Jordan.ORCID 0000-0002-9344-0587
Michael HaleySchool of Biological Sciences, Lydia Becker Institute of Immunology and Infection, University of Manchester, Manchester M13 9PT, UK.
Kevin CouperSchool of Biological Sciences, Lydia Becker Institute of Immunology and Infection, University of Manchester, Manchester M13 9PT, UK.
Sally FreemanDivision of Pharmacy and Optometry, School of Health Sciences, University of Manchester, Manchester M13 9PT, UK.ORCID 0000-0002-3831-9151
Niroshini J NirmalanSchool of Science, Engineering and Environment, University of Salford, Manchester M5 4WT, UK.ORCID 0000-0001-9000-298X
University of Manchester · GBUniversity of Salford · GBAl-Zaytoonah University of Jordan · JO

Funding

Medical Research Council MR/V034650/1Wellcome Trust 107881
6 · The paper itself

Abstract

The emergence of resistance to first-line antimalarial drugs calls for the development of new therapies for drug-resistant malaria. The efficacy of quinoline-based antimalarial drugs has prompted the development of novel quinolines. A panel of 4-aminoquinoline hydrazone analogues were tested on the multidrug-resistant K1 strain of

Indexed as

AntimalarialsMalariaMalaria, FalciparumAminoquinolinesAnimalsMicePlasmodium falciparum4-aminoquinolineAminoquinolinesAntimalarials4-aminoquinolineantimalarialantimalarial drug interactionhydrazoneNQO2 inhibitorsSAR

Identifiers

PMID37764248
PMCPMC10534891
OpenAlexW4386476049

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.